EPO and myelodysplastic syndrome: The main parameters for consideration when planning therapeutic interventions for patients with lower-risk MDS are cell counts, ferritin and endogenous EPO levels, the presence of del(5q), and, most important, the burden of disease as reflected by general health status and symptoms of hematopoietic insufficiency.